{"id":13329,"date":"2019-02-28T13:30:46","date_gmt":"2019-02-28T12:30:46","guid":{"rendered":"https:\/\/www.satt.fr\/yukin-therapeutics-start-up-biotech-issue-de-la-recherche-publique-nicoise-defie-les-cancers\/"},"modified":"2019-02-28T14:42:38","modified_gmt":"2019-02-28T13:42:38","slug":"yukin-therapeutics-start-up-biotech-issue-de-la-recherche-publique-nicoise-defie-les-cancers","status":"publish","type":"post","link":"https:\/\/www.satt.fr\/en\/yukin-therapeutics-start-up-biotech-issue-de-la-recherche-publique-nicoise-defie-les-cancers\/","title":{"rendered":"SATT Sud-Est : Yukin Therapeutics, start-up biotech issue de la recherche publique ni\u00e7oise, d\u00e9fie les cancers"},"content":{"rendered":"<h2>La SATT Sud-Est transf\u00e8re \u00e0 Yukin Therapeutics une innovation tr\u00e8s prometteuse dans la lutte contre le cancer, cofinanc\u00e9e avec le Cancerop\u00f4le Provence-Alpes-C\u00f4te d\u2019Azur, et annonce son entr\u00e9e au capital de la start-up accompagn\u00e9e par Advent France Biotechnology. C\u2019est une belle r\u00e9ussite conjointe de la SATT Sud-Est et du Cancerop\u00f4le PACA, partenaires pour l\u2019attractivit\u00e9 du territoire et l\u2019implantation de jeunes entreprises innovantes<\/h2>\n<p>La SATT Sud-Est conc\u00e8de \u00e0 la jeune start-up pharmaceutique Yukin Therapeutics une licence d&#8217;exploitation exclusive de 2 brevets, en copropri\u00e9t\u00e9 de l&#8217;Universit\u00e9 Nice Sophia Antipolis, de l&#8217;Inserm, du CNRS et du CHU de Nice. L\u2019invention est issue de travaux scientifiques rep\u00e9r\u00e9s et propuls\u00e9s par le Cancerop\u00f4le Provence-Alpes-C\u00f4te d\u2019Azur ; prot\u00e9g\u00e9e par la SATT Sud-Est, elle est d\u00e9velopp\u00e9e et cofinanc\u00e9e par la SATT Sud-Est et le Cancerop\u00f4le PACA. L\u2019invention concerne un arsenal th\u00e9rapeutique ciblant le cancer de la peau, ainsi que la plupart des cancers solides dont le cancer pancr\u00e9atique.<\/p>\n<p>L\u2019immunoth\u00e9rapie est qualifi\u00e9e de d\u00e9couverte majeure et s\u2019est vue r\u00e9compens\u00e9e du Prix Nobel de Physiologie ou de M\u00e9decine 2018. Toutefois, des obstacles th\u00e9rapeutiques au traitement des cancers subsistent avec, pour cons\u00e9quence, une efficacit\u00e9 limit\u00e9e \u00e0 un nombre restreint de patients. Les \u00e9quipes ni\u00e7oises de biologistes et de chimistes du Pr Thierry PASSERON et du Dr Rachid BENHIDA ont d\u00e9cid\u00e9 de mettre au point une nouvelle strat\u00e9gie th\u00e9rapeutique. L\u2019objectif ? Booster l\u2019efficacit\u00e9 de l\u2019immunoth\u00e9rapie. Les chercheurs visent une cible th\u00e9rapeutique, la kinase \u00ab NF-kappa-B-inducing kinase \u00bb ou NIK. L\u2019outil th\u00e9rapeutique, prot\u00e9g\u00e9 par un portefeuille de brevets, consiste en une s\u00e9rie de compos\u00e9s actifs synth\u00e9tis\u00e9s au laboratoire. En modulant l\u2019activit\u00e9 de la kinase NIK, ces compos\u00e9s induisent une r\u00e9ponse anti-tumorale et accentuent les effets d\u2019un traitement par anticorps anti-PD-1, le traitement de r\u00e9f\u00e9rence sur le march\u00e9. Cela a \u00e9t\u00e9 observ\u00e9 in vitro sur cellules de m\u00e9lanome et de cancer du c\u00f4lon, poumon, sein, prostate et pancr\u00e9as, et in vivo dans le m\u00e9lanome et le cancer colorectal chez la souris. Ce projet fait l\u2019objet d\u2019un accompagnement et d\u2019un investissement conjoints de la SATT Sud-Est et du Cancerop\u00f4le PACA.<\/p>\n<p>La start-up Yukin Therapeutics est une SAS fond\u00e9e par les chercheurs inventeurs, sp\u00e9cialis\u00e9e en d\u00e9veloppement pharmaceutique, et bas\u00e9e \u00e0 Biot (06). Yukin Therapeutics vise \u00e0 utiliser ces inhibiteurs \u00ab first-in-class \u00bb de la kinase NIK sur des indications cibl\u00e9es en oncologie. Par ailleurs, les chercheurs ont d\u00e9j\u00e0 obtenu des r\u00e9sultats prometteurs sur d\u2019autres indications comme le cancer colorectal notamment. Yukin Therapeutics est accompagn\u00e9e par son actionnaire principal, le fonds d&#8217;investissements en sant\u00e9 Advent France Biotechnology. La SATT Sud-Est, qui a transf\u00e9r\u00e9 la technologie gr\u00e2ce \u00e0 un programme de maturation, et un programme Emergence et Accompagnement (EmA) initi\u00e9 et pilot\u00e9 par le Cancerop\u00f4le PACA, est entr\u00e9e au capital de Yukin Therapeutics. Yukin Therapeutics a pour objectif de poursuivre le d\u00e9veloppement de ses compos\u00e9s en phases cliniques.<\/p>\n<ul>\n<li><a href=\"https:\/\/www.sattse.com\/2019\/02\/yukin-therapeutics-start-up-biotech-issue-de-la-recherche-publique-nicoise-defie-les-cancers\/\">Lire l&#8217;actu sur le site de la SATT Sud-Est<\/a><\/li>\n<li><a href=\"https:\/\/www.sattse.com\/wp-content\/uploads\/2019\/02\/CP_SATTSudEst_Yukintherapeutics_Canceropole_190228.pdf\">T\u00e9l\u00e9charger le communiqu\u00e9 de presse<\/a><\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>La SATT Sud-Est transf\u00e8re \u00e0 Yukin Therapeutics une innovation tr\u00e8s prometteuse dans la lutte contre le cancer, cofinanc\u00e9e avec le Cancerop\u00f4le Provence-Alpes-C\u00f4te d\u2019Azur, et annonce son entr\u00e9e au capital de la start-up accompagn\u00e9e par Advent France Biotechnology. C\u2019est une belle r\u00e9ussite conjointe de la SATT Sud-Est et du Cancerop\u00f4le PACA, partenaires pour l\u2019attractivit\u00e9 du territoire [&hellip;]<\/p>\n","protected":false},"author":19,"featured_media":13334,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[567],"tags":[],"class_list":["post-13329","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news-en"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>SATT Sud-Est : Yukin Therapeutics, start-up biotech issue de la recherche publique ni\u00e7oise, d\u00e9fie les cancers - R\u00e9seau SATT<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.satt.fr\/en\/yukin-therapeutics-start-up-biotech-issue-de-la-recherche-publique-nicoise-defie-les-cancers\/\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Florent martin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.satt.fr\/en\/yukin-therapeutics-start-up-biotech-issue-de-la-recherche-publique-nicoise-defie-les-cancers\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.satt.fr\/en\/yukin-therapeutics-start-up-biotech-issue-de-la-recherche-publique-nicoise-defie-les-cancers\/\"},\"author\":{\"name\":\"Florent martin\",\"@id\":\"https:\/\/www.satt.fr\/en\/#\/schema\/person\/75a6a0c22ca8038651daf0ca1de36591\"},\"headline\":\"SATT Sud-Est : Yukin Therapeutics, start-up biotech issue de la recherche publique ni\u00e7oise, d\u00e9fie les cancers\",\"datePublished\":\"2019-02-28T12:30:46+00:00\",\"dateModified\":\"2019-02-28T13:42:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.satt.fr\/en\/yukin-therapeutics-start-up-biotech-issue-de-la-recherche-publique-nicoise-defie-les-cancers\/\"},\"wordCount\":571,\"image\":{\"@id\":\"https:\/\/www.satt.fr\/en\/yukin-therapeutics-start-up-biotech-issue-de-la-recherche-publique-nicoise-defie-les-cancers\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.satt.fr\/wp-content\/uploads\/2019\/02\/YU.png\",\"articleSection\":[\"News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.satt.fr\/en\/yukin-therapeutics-start-up-biotech-issue-de-la-recherche-publique-nicoise-defie-les-cancers\/\",\"url\":\"https:\/\/www.satt.fr\/en\/yukin-therapeutics-start-up-biotech-issue-de-la-recherche-publique-nicoise-defie-les-cancers\/\",\"name\":\"SATT Sud-Est : Yukin Therapeutics, start-up biotech issue de la recherche publique ni\u00e7oise, d\u00e9fie les cancers - R\u00e9seau SATT\",\"isPartOf\":{\"@id\":\"https:\/\/www.satt.fr\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.satt.fr\/en\/yukin-therapeutics-start-up-biotech-issue-de-la-recherche-publique-nicoise-defie-les-cancers\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.satt.fr\/en\/yukin-therapeutics-start-up-biotech-issue-de-la-recherche-publique-nicoise-defie-les-cancers\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.satt.fr\/wp-content\/uploads\/2019\/02\/YU.png\",\"datePublished\":\"2019-02-28T12:30:46+00:00\",\"dateModified\":\"2019-02-28T13:42:38+00:00\",\"author\":{\"@id\":\"https:\/\/www.satt.fr\/en\/#\/schema\/person\/75a6a0c22ca8038651daf0ca1de36591\"},\"breadcrumb\":{\"@id\":\"https:\/\/www.satt.fr\/en\/yukin-therapeutics-start-up-biotech-issue-de-la-recherche-publique-nicoise-defie-les-cancers\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.satt.fr\/en\/yukin-therapeutics-start-up-biotech-issue-de-la-recherche-publique-nicoise-defie-les-cancers\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.satt.fr\/en\/yukin-therapeutics-start-up-biotech-issue-de-la-recherche-publique-nicoise-defie-les-cancers\/#primaryimage\",\"url\":\"https:\/\/www.satt.fr\/wp-content\/uploads\/2019\/02\/YU.png\",\"contentUrl\":\"https:\/\/www.satt.fr\/wp-content\/uploads\/2019\/02\/YU.png\",\"width\":1294,\"height\":722},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.satt.fr\/en\/yukin-therapeutics-start-up-biotech-issue-de-la-recherche-publique-nicoise-defie-les-cancers\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/www.satt.fr\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SATT Sud-Est : Yukin Therapeutics, start-up biotech issue de la recherche publique ni\u00e7oise, d\u00e9fie les cancers\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.satt.fr\/en\/#website\",\"url\":\"https:\/\/www.satt.fr\/en\/\",\"name\":\"R\u00e9seau SATT\",\"description\":\"Les Soci\u00e9t\u00e9s d&#039;Acc\u00e9l\u00e9ration du Transfert de Technologies\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.satt.fr\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.satt.fr\/en\/#\/schema\/person\/75a6a0c22ca8038651daf0ca1de36591\",\"name\":\"Florent martin\",\"url\":\"https:\/\/www.satt.fr\/en\/author\/florent\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"SATT Sud-Est : Yukin Therapeutics, start-up biotech issue de la recherche publique ni\u00e7oise, d\u00e9fie les cancers - R\u00e9seau SATT","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.satt.fr\/en\/yukin-therapeutics-start-up-biotech-issue-de-la-recherche-publique-nicoise-defie-les-cancers\/","twitter_misc":{"Written by":"Florent martin","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.satt.fr\/en\/yukin-therapeutics-start-up-biotech-issue-de-la-recherche-publique-nicoise-defie-les-cancers\/#article","isPartOf":{"@id":"https:\/\/www.satt.fr\/en\/yukin-therapeutics-start-up-biotech-issue-de-la-recherche-publique-nicoise-defie-les-cancers\/"},"author":{"name":"Florent martin","@id":"https:\/\/www.satt.fr\/en\/#\/schema\/person\/75a6a0c22ca8038651daf0ca1de36591"},"headline":"SATT Sud-Est : Yukin Therapeutics, start-up biotech issue de la recherche publique ni\u00e7oise, d\u00e9fie les cancers","datePublished":"2019-02-28T12:30:46+00:00","dateModified":"2019-02-28T13:42:38+00:00","mainEntityOfPage":{"@id":"https:\/\/www.satt.fr\/en\/yukin-therapeutics-start-up-biotech-issue-de-la-recherche-publique-nicoise-defie-les-cancers\/"},"wordCount":571,"image":{"@id":"https:\/\/www.satt.fr\/en\/yukin-therapeutics-start-up-biotech-issue-de-la-recherche-publique-nicoise-defie-les-cancers\/#primaryimage"},"thumbnailUrl":"https:\/\/www.satt.fr\/wp-content\/uploads\/2019\/02\/YU.png","articleSection":["News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.satt.fr\/en\/yukin-therapeutics-start-up-biotech-issue-de-la-recherche-publique-nicoise-defie-les-cancers\/","url":"https:\/\/www.satt.fr\/en\/yukin-therapeutics-start-up-biotech-issue-de-la-recherche-publique-nicoise-defie-les-cancers\/","name":"SATT Sud-Est : Yukin Therapeutics, start-up biotech issue de la recherche publique ni\u00e7oise, d\u00e9fie les cancers - R\u00e9seau SATT","isPartOf":{"@id":"https:\/\/www.satt.fr\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.satt.fr\/en\/yukin-therapeutics-start-up-biotech-issue-de-la-recherche-publique-nicoise-defie-les-cancers\/#primaryimage"},"image":{"@id":"https:\/\/www.satt.fr\/en\/yukin-therapeutics-start-up-biotech-issue-de-la-recherche-publique-nicoise-defie-les-cancers\/#primaryimage"},"thumbnailUrl":"https:\/\/www.satt.fr\/wp-content\/uploads\/2019\/02\/YU.png","datePublished":"2019-02-28T12:30:46+00:00","dateModified":"2019-02-28T13:42:38+00:00","author":{"@id":"https:\/\/www.satt.fr\/en\/#\/schema\/person\/75a6a0c22ca8038651daf0ca1de36591"},"breadcrumb":{"@id":"https:\/\/www.satt.fr\/en\/yukin-therapeutics-start-up-biotech-issue-de-la-recherche-publique-nicoise-defie-les-cancers\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.satt.fr\/en\/yukin-therapeutics-start-up-biotech-issue-de-la-recherche-publique-nicoise-defie-les-cancers\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.satt.fr\/en\/yukin-therapeutics-start-up-biotech-issue-de-la-recherche-publique-nicoise-defie-les-cancers\/#primaryimage","url":"https:\/\/www.satt.fr\/wp-content\/uploads\/2019\/02\/YU.png","contentUrl":"https:\/\/www.satt.fr\/wp-content\/uploads\/2019\/02\/YU.png","width":1294,"height":722},{"@type":"BreadcrumbList","@id":"https:\/\/www.satt.fr\/en\/yukin-therapeutics-start-up-biotech-issue-de-la-recherche-publique-nicoise-defie-les-cancers\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.satt.fr\/en\/"},{"@type":"ListItem","position":2,"name":"SATT Sud-Est : Yukin Therapeutics, start-up biotech issue de la recherche publique ni\u00e7oise, d\u00e9fie les cancers"}]},{"@type":"WebSite","@id":"https:\/\/www.satt.fr\/en\/#website","url":"https:\/\/www.satt.fr\/en\/","name":"R\u00e9seau SATT","description":"Les Soci\u00e9t\u00e9s d&#039;Acc\u00e9l\u00e9ration du Transfert de Technologies","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.satt.fr\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.satt.fr\/en\/#\/schema\/person\/75a6a0c22ca8038651daf0ca1de36591","name":"Florent martin","url":"https:\/\/www.satt.fr\/en\/author\/florent\/"}]}},"_links":{"self":[{"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/posts\/13329","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/users\/19"}],"replies":[{"embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/comments?post=13329"}],"version-history":[{"count":1,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/posts\/13329\/revisions"}],"predecessor-version":[{"id":13332,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/posts\/13329\/revisions\/13332"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/media\/13334"}],"wp:attachment":[{"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/media?parent=13329"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/categories?post=13329"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/tags?post=13329"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}